LEXARIA BIOSCIENCE CORP. Right-of-Use Asset Obtained in Exchange for Operating Lease Liability
LEXARIA BIOSCIENCE CORP. (LEXX) reported Right-of-Use Asset Obtained in Exchange for Operating Lease Liability of $156.57 thousand for the 12-month period ending 2023-08-31, per its 10-K filed 2023-11-20.
Discontinued › Notes › Leases
us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability · last filed 2023-11-20
- LEXARIA BIOSCIENCE CORP. right-of-use asset obtained in exchange for operating lease liability for fiscal 2023 was $156.57K.
- LEXARIA BIOSCIENCE CORP. right-of-use asset obtained in exchange for operating lease liability for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- LEXARIA BIOSCIENCE CORP. right-of-use asset obtained in exchange for operating lease liability for fiscal 2021 was $35.88K, a 7.61% increase from fiscal 2020.
- LEXARIA BIOSCIENCE CORP. right-of-use asset obtained in exchange for operating lease liability for fiscal 2020 was $33.34K.
| Period end | Right-of-Use Asset Obtained in Exchange for Operating Lease Liability 12 month |
|---|---|
| 2023-08-31 | $156.57K 10-K · filed 2023-11-20 |
| 2022-08-31 | $0.00 10-K · filed 2023-11-20 |
| 2021-08-31 | $35.88K 10-K · filed 2021-11-29 |
| 2020-08-31 | $33.34K 10-K · filed 2021-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Telomir Pharmaceuticals, Inc. (TELO) | United States | $0.084B | |
| NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) | United States | $0.086B | |
| ONCOLYTICS BIOTECH INC (ONCY) | $0.086B | ||
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Rallybio Corp (RLYB) | United States | $0.089B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Acrivon Therapeutics, Inc. (ACRV) | United States | $0.091B | -1.03 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |